Neptune to Hold Conference Call to Discuss Fourth Quarter and Fiscal 2013
LAVAL, Quebec, May 9, 2013 (GLOBE NEWSWIRE) -- Neptune Technologies &
Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) will be holding a
conference call on Thursday, May 23 at 9:00 am ET to present its results for
the fourth quarter and fiscal year ended February 28, 2013. The Company will
also be providing an update on the status of its previously disclosed action
plan to resume operations and supply customers.
The conference call hosts will be Henri Harland, President & CEO and André
To access the conference call within Canada & the U.S., dial toll‐free
1-877-380-5664. Outside Canada and the U.S., dial 1-631-813-4882.
Conference call details:
Conference Topic: Neptune Technologies & Bioressources Fourth Quarter
and Fiscal Year Ended February 28, 2013 Results Call
Conference ID: 70455786
Time: 9:00 AM Eastern Time
Management will accept questions related to the financial results and its
operations by telephone during the Q&A period at the end of the presentation.
Questions can also be forwarded in advance or during the presentation to
An archived recording of the conference call will be available on Neptune's
website (www.neptunebiotech.com) shortly after the call.
Neptune's audited consolidated financial statements for the period ended
February 28, 2013 and related MD&A will be made available on SEDAR at
www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml and on Neptune's website at
http://www.neptunebiotech.com prior to the conference call.
About Neptune Technologies & Bioressources Inc.
Neptune is a biotechnology company engaged primarily in the development and
commercialization of marine-derived omega-3 polyunsaturated fatty acids, or
PUFAs. Neptune has a patented process of extracting oils from Antarctic krill,
which omega-3 PUFAs are then principally sold as bulk oil to Neptune's
distributors who commercialize them under their private label primarily in the
U.S., European and Asian neutraceutical markets. Neptune's lead products,
Neptune Krill Oil (NKO®) and ECOKRILL Oil (EKO™), generally come in capsule
form and serve as a dietary supplement to consumers.
Through its subsidiaries Acasti Pharma and NeuroBioPharm, in which Neptune
respectively holds 57% and 96% of the voting rights, Neptune is also pursuing
opportunities in the medical food and prescription drug markets. Acasti and
NeuroBio respectively focus on the research and development of safe and
therapeutically effective compounds for highly prevalent atherosclerotic
conditions, such as cardiometabolic disorders and cardiovascular diseases, and
for neurodegenerative and inflammation related conditions. Acasti's lead
prescription drug candidate is CaPre®, a purified high omega-3 phospholipid
concentrate derived from krill oil being developed to address the prevention
and treatment of cardiometabolic disorders, including hypertriglyceridemia,
which is characterized by abnormally high levels of triglycerides.
Forward Looking Statements
Certain statements included in this press release may be considered
forward-looking information within the meaning of Canadian securities laws and
forward-looking statements within the meaning of U.S. federal securities laws,
both of which we refer to as forward-looking statements. Such statements
involve known and unknown risks, uncertainties and other factors that may
cause results, performance or achievements to be materially different from
those implied by such statements, and therefore these statements should not be
read as guarantees of future performance or results. All forward-looking
statements are based on Neptune's current beliefs as well as assumptions made
by and information currently available to Neptune and relate to, among other
things, Neptune's strategy, strategic goals, research and development
activities, research and clinical testing outcome, future operations, future
financial position, future revenues/results, projected costs, prospects and
plans and objectives of management.
Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. Due to
risks and uncertainties, including the risks and uncertainties identified by
Neptune in its amended and restated annual information form dated September
11, 2012, in its press release announcing an action plan to resume operations
and supply customers dated November 26, 2012 and in its other public
securities filings available at www.sedar.com and www.sec.gov/edgar.shtml,
actual events may differ materially from current expectations. Except as
required by law, Neptune disclaims any intention or obligation to update or
revise any forward-looking statements.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
Howard Group Contact:
Press spacebar to pause and continue. Press esc to stop.